Neurotoxicity and cognitive outcomes in modern therapies for primary central nervous system lymphoma
Last Updated: Friday, November 6, 2026
In a clinical review, researchers summarize current evidence on neurocognitive outcomes across modern therapies for primary central nervous system lymphoma and discuss the challenge of distinguishing neurotoxicity from relapse.
